Proprietary Novel Delivery System
Undisclosed
Key Facts
About Gland Pharma
Gland Pharma's mission is to be a leading global provider of high-quality, affordable injectable medicines. The company has achieved this through a combination of deep expertise in complex sterile manufacturing, strategic partnerships like the one with Fosun Pharma, and a successful IPO in 2020. Its core strategy focuses on expanding its CDMO business, leveraging its R&D for differentiated formulations, and penetrating new regulated and emerging markets to drive sustainable growth.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| Amgen Collaboration Program | Xeris Biopharma | Pre-clinical |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |